Kiniksa Pharmaceuticals International, plc KNSA

75.08 (0.26) (0.35%) as of 25 Sep
Market cap
$5.9B
P/E
70.2×
Growth Flags show if company had growth for consecutive years

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Cash and Short Term Investments 414.07 243.63 206.37 190.61 182.20 323.69 233.38 307.30 45.66 56.08
Receivables 15.59 41.72 21.27 12.66 3.99 — — — — —
Inventory 54.90 26.36 31.12 21.60 3.68 — — — — —
Other current assets — — — 7.66 6.59 9.56 8.25 6.45 1.44 0.26
Total current assets 527.18 331.80 276.30 243.06 196.45 333.25 241.63 313.75 47.10 56.33
Property, Plant, Equpment (Net) 1.94 0.66 0.73 1.66 2.83 4.05 6.40 6.36 0.13 0.08
Goodwill and Intangible Assets (Total) 15.25 16.25 17.25 18.25 19.25 — — — — —
Long Term Assets (Tax, Deferred) 198.15 211.15 219.28 185.50 — 0.01 4.37 1.22 0.24 0.04
Long-term assets (Other) 11.31 10.32 0.83 5.82 8.72 5.59 0.21 0.21 0.03 0.01
Total non-current assets 236.46 248.75 250.03 216.61 36.35 16.22 12.91 8.22 0.39 0.13
Total Assets 763.63 580.55 526.32 459.67 232.80 349.46 254.53 321.97 47.49 56.47
Accounts Payable 2.03 2.04 8.25 7.90 1.87 0.50 5.69 10.92 1.22 0.21
Accrued Expenses 112.04 80.51 44.67 30.11 38.03 29.20 20.42 31.42 16.21 2.09
Current Revenue (Deferred) — — 0.31 — — — — — — —
Other current liabilities 22.13 16.08 8.19 5.75 1.54 0.04 0.03 0.22 16.21 2.09
Total current liabilities 139.18 100.62 63.67 47.07 44.82 31.85 27.83 42.55 17.43 2.30
Non-current Revenue (Deferred) 31.81 31.81 11.95 12.00 — — — — — —
Non-current Liabilities (Other) 18.52 1.82 1.86 1.84 0.27 0.81 0.33 0.14 — —
Total non-current liabilities 56.84 41.50 23.82 16.46 2.94 5.68 1.28 0.14 — —
Total liabilities 196.03 142.12 87.48 63.52 47.76 37.53 29.11 42.70 17.43 2.30
Additional Paid In Capital 1,029.75 959.72 916.76 888.12 860.48 829.42 581.47 473.48 1.29 0.39
Preferred Stock (Total) — — — — — — — — 119.77 79.90
Common Stock (Net) 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.01 0.00 0.00
Retained Earnings (462.14) (521.14) (477.95) (492.03) (675.40) (517.47) (356.09) (194.22) (91.00) (26.12)
Common Equity (Total) 567.61 438.44 438.84 396.15 185.04 311.94 225.42 279.27 (89.71) (25.73)
Shareholders Equity (Total) 567.61 438.44 438.84 396.15 185.04 311.94 225.42 279.27 30.06 54.17
Shareholders Equity and Liabilities (Total) 763.63 580.55 526.32 459.67 232.80 349.46 254.53 321.97 47.49 56.47
Shares (Common) 76.29 72.52 70.46 69.70 69.06 68.22 54.94 49.49 4.29 48.44
Shares (Preferred) — — — — — — — — 22.89 17.13
Shareholders Equity (Tangible) 552.36 422.19 421.59 377.90 165.79 311.94 225.42 279.27 30.06 54.17
Net Debt (414.07) (243.63) (206.37) (190.61) (182.20) (323.69) (233.38) (307.30) (45.66) (56.07)
Total Debt — — — 5.92 6.05 6.99 2.65 — — —

Fold the line items

In millions of $ except per-share values · columns are period end dates